newsfilter
← Latest News
GlobeNewswire·

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13,